← Oncology Approval Tracker

FDA DECISION ·

Jakafi

ruxolitinib · Incyte

FDA approvalNew or expanded indicationChronic graft-versus-host disease
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Patients age 12 and older with chronic graft-versus-host disease after failure of one or two systemic treatment lines.

LAMPGEN ANALYSIS

Why it matters

The JAK inhibitor gains a chronic post-transplant indication distinct from its acute GVHD use.

What research teams should watch

Record whether GVHD is acute or chronic, which systemic lines failed and organ-specific baseline findings.

PRIMARY RECORDS

Sources